{
    "clinical_study": {
        "@rank": "142998", 
        "arm_group": {
            "arm_group_label": "Herceptin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of Herceptin in patients with metastatic or\n      advanced gastric cancer with disease progression during platinum-based or\n      5-fluoropyrimidine-based chemotherapy. The anticipated time on study treatment is until\n      disease progression."
        }, 
        "brief_title": "A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression", 
        "completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Stomach Neoplasms", 
                "Disease Progression"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients 18-75 years of age;\n\n          -  metastatic or advanced gastric cancer;\n\n          -  disease progression under or after 1 prior platinum-based or 5-fluoropyrimidine-based\n             chemotherapy for metastatic disease;\n\n          -  >=4 weeks from last platinum-based or fluoropyrimidine-based chemotherapy;\n\n          -  >=1 measurable lesion;\n\n          -  HER2 overexpression (IHC [2+] or [3+]).\n\n        Exclusion Criteria:\n\n          -  concurrent chemotherapy or immunotherapy;\n\n          -  brain or meningeal metastases;\n\n          -  clinically significant cardiac disease, advanced pulmonary disease or severe\n             dyspnoea;\n\n          -  co-existing malignancies or malignancies diagnosed within last 5 years, except basal\n             cell cancer or cervical cancer in situ;\n\n          -  women who are pregnant or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005484", 
            "org_study_id": "ML17263"
        }, 
        "intervention": {
            "arm_group_label": "Herceptin", 
            "description": "4 mg/kg initial dose, followed by 2 mg/kg", 
            "intervention_name": "trastuzumab [Herceptin]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1090"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91054"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45122"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenzach-wyhlen", 
                        "country": "Germany", 
                        "zip": "79639"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halle", 
                        "country": "Germany", 
                        "zip": "06120"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kassel", 
                        "country": "Germany", 
                        "zip": "34125"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany", 
                        "zip": "24105"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany", 
                        "zip": "68167"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "81377"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "81675"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oldenburg", 
                        "country": "Germany", 
                        "zip": "26133"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Pilot Study of Herceptin Monotherapy on Objective Treatment Response in Patients With Metastatic or Locally Advanced Gastric Cancer Who Had Disease Progression During Platinum-based or 5-fluoropyrimidine-based Chemotherapy", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Austrian Federal Office for Safety in Health Care, BASG - AGES, Institut Zulassung &amp; LCM/KPPS"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Best overall response rate", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005484"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2004", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}